ArticleCancer medicine2017

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.

Vasilios Liapis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.